Research progress of microRNA in triple negative breast cancer
10.3760/cma.j.issn.115807-20200211-00032
- VernacularTitle:微小RNA在三阴性乳腺癌中的研究进展
- Author:
Cheng WANG
1
Author Information
1. 上海交通大学医学院附属第九人民医院黄浦分院乳腺外科 200011
- From:Chinese Journal of Endocrine Surgery
2020;14(2):166-169
- CountryChina
- Language:Chinese
-
Abstract:
Triple negative breast cancer (TNBC) , regarded as a highly heterogeneous disease, is a kind of molecular subtype of breast cancer with negative in estrogen receptor (ER) , progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2) . Compared with other subtypes of breast cancer, TNBC is high aggressive in biological behavior, prone to recurrence and visceral metastasis, drug resistance and poor prognosis. MicroRNA (miRNA) is a promising biomarker and forecasting tool, which could be used for diagnosis and treatment of breast cancer at various stage. In this study, we reviewed the research progress of miRNA in TNBC in the aspects of high aggression, potential treated targets, screening of prognosis biomarkers, drug resistance, prediction of pCR in neoadjuvant therapy, and association with BRCA1/2 mutation, etc. to offer reference for early screening and diagnosis, clinical treatment and prognosis judgment of TNBC.
